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The mechanisms that allow the body to sense iron
levels in order to maintain iron homeostasis are
unknown. Patients with the most common form of
hereditary iron overload havemutations in the hered-
itary hemochromatosis protein HFE. They have lower
levels of hepcidin than unaffected individuals. Hepci-
din, a hepatic peptide hormone, negatively regulates
iron efflux from the intestines into the blood. We
report two hepatic cell lines, WIF-B cells and
HepG2 cells transfected with HFE, where hepcidin
expression responded to iron-loaded transferrin.
The response was abolished when endogenous
transferrin receptor 2 (TfR2) was suppressed or in
primary hepatocytes lacking either functional TfR2
or HFE. Furthermore, transferrin-treated HepG2 cells
transfected with HFE chimeras containing only the
a3 and cytoplasmic domains could upregulate hep-
cidin expression. Since the HFE a3 domain interacts
with TfR2, these results supported our finding that
TfR2/HFE complex is required for transcriptional
regulation of hepcidin by holo-Tf.
INTRODUCTION
Iron is essential for fundamental metabolic processes in cells and
organisms. It is also toxic when in excess. Hereditary hemochro-
matosis (HH) is a heterogeneous group of iron overload disorders
caused by mutations in a variety of proteins involved in iron
homeostasis, including HFE (Feder et al., 1996), hemojuvelin
(HJV) (Papanikolaou et al., 2004), hepcidin (Roetto et al., 2003),
transferrin receptor 2 (TfR2) (Camaschella et al., 2000), or ferro-
portin (Fpn) (Montosi et al., 2001). HH manifests as increased
intestinal iron absorption and liver iron overload (Vujic Spasic
et al., 2008). If untreated, HH patients develop hepatic cirrhosis
and hepatocellular carcinoma, cardiomyopathy and arrhythmias,
diabetes, arthritis, and hypogonadotropic hypogonadism (Ajioka
and Kushner, 2002; Bothwell and MacPhail, 1998).
The most common form of HH is caused by single base pair
mutation in HFE resulting in a C260Y substitution (Feder et al.,
1996). In this manuscript, we have followed the numbering
system of HFE, which starts at the first amino acid after signalpeptide cleavage (22-1) (Lebron et al., 1998) and corresponds
to previous numbering systems used in major histocompatibility
complex class I protein (MHC1)-like molecules. HFE encodes an
atypical MHC1. Like the MHC1 proteins, HFE is a membrane
protein that consists of a signal sequence, a1–a3 domains fol-
lowed by a transmembrane domain, and a short cytoplasmic
domain. It also forms a heterodimeric complex with b2-micro-
globulin (Lebron et al., 1998). The C260Y mutation disrupts a
disulfide bond in the a3 domain, leading to misfolding of HFE,
lack of association with b2-microglobulin, and failure to traffic to
the cell surface (Feder et al., 1997). The generation of a knockout
mouse (Hfe/), coupled to the finding that the C260Y substitu-
tion and the Hfe/ phenotypes are similar, confirms that C260Y
has a loss-of-function phenotype (Muckenthaler et al., 2004).
Although the importance of HFE in iron regulation is apparent
in HH patients and mouse models (Levy et al., 1999; Zhou
et al., 1998), the underlying mechanism by which HFE regulates
iron metabolism remains undiscovered.
Disease-causing mutations in HFE result in decreased hepci-
din production both in HH patients and in Hfe/ mice when
compared to similarly iron-loaded individuals with unmutated
HFE (Ahmad et al., 2002; Bridle et al., 2003; Muckenthaler
et al., 2003; Nicolas et al., 2003). Hepcidin is a peptide hormone
produced predominantly by the liver. It plays a major role in the
regulation of iron homeostasis within the body by modulating
iron levels through binding to and triggering the internalization
and degradation of the iron exporter Fpn (Nemeth et al., 2004).
Thus, hepcidin controls iron loading of Tf by negatively regulating
iron efflux from enterocytes, liver macrophages, and hepato-
cytes into the blood.
Hepcidin production is modulated by many factors, including
iron levels within the body. In response to iron loading in animal
studies, hepcidin expression increases to prevent the further
uptake of iron. Conversely, during iron deficiency, hepcidin
expression decreases (Pigeon et al., 2001; Weinstein et al.,
2002). In the liver, both hepcidin and HFE are predominantly
expressed in hepatocytes (Holmstrom et al., 2003; Zhang et al.,
2004). Hepatocyte-specific expression of HFE in Hfe/ mice
restores normal iron homeostasis, indicating that hepatocyte-
specific expression of HFE is sufficient to control iron homeo-
stasis (Vujic Spasic et al., 2008). Thus, HFE appears to function
upstream of hepcidin expression to regulate iron homeostasis.
HFE has several binding partners that could participate in iron
homeostasis. HFE associates with transferrin receptor 1 (TfR1)
(Feder et al., 1998; Waheed et al., 1999) through its a1 andCell Metabolism 9, 217–227, March 4, 2009 ª2009 Elsevier Inc. 217
Cell Metabolism
HFE and TfR2 Regulate Hepcidin Expressiona2 domains (Bennett et al., 2000) and with TfR2 through its
a3 domain (Chen et al., 2007). The binding sites on TfR1 for
HFE and iron-loaded transferrin (holo-Tf) overlap (Giannetti
et al., 2003; Lebron and Bjorkman, 1999; West et al., 2001), con-
firming the competition between HFE and holo-Tf for binding to
TfR1. More recent coimmunoprecipitation studies demonstrate
that HFE also interacts with TfR2 (Chen et al., 2007; Goswami
and Andrews, 2006). TfR2 is expressed predominantly in hepato-
cytes and is closely related to TfR1 in sequence and in its ability to
bind holo-Tf but not iron-depleted Tf (apo-Tf) (Kawabata et al.,
1999). Unlike TfR1, holo-Tf does not compete with HFE for
binding to TfR2 (Chen et al., 2007).
Similar to HFE, disease-causing mutations in TfR2 also result
in decreased hepcidin levels (Wallace et al., 2007). TfR2 is
hypothesized to act as a sensor for iron levels in the body
because of its largely hepatocyte-specific expression and its
ability to bind holo-Tf (Kawabata et al., 1999). The main limitation
in determining how HFE and TfR2 regulate hepcidin expression
to date has been the lack of a cell line in which the hepcidin
expression is responsive to holo-Tf.
In the present study, we found that WIF-B cells, a rat hepa-
toma/human fibroblast hybrid, increased the expression of hep-
cidin in response to holo-Tf. HFE and TfR2 mRNA levels were
higher in WIF-B cells compared to HepG2 cells, a human hepa-
toma cell line whose expression of hepcidin is not sensitive to
holo-Tf. We used the HepG2/tetracycline-controlled transactiva-
tor protein (tTA) cells that express HFE under the tight control of
tetracycline-inducible promoter and showed that hepcidin levels
increase when cells expressing HFE are treated with holo-Tf. The
involvement of HFE and TfR2 in this process was investigated
using TfR2 siRNA, primary hepatocytes, and HFE chimeras.
Our results show that Tf-induced hepcidin expression was
dependent on the interaction of TfR2 with HFE.
RESULTS
Holo-Tf Induces Hepcidin Expression in WIF-B Cells
The positive correlation between hepcidin levels and holo-Tf in
the blood leads to the hypothesis that the liver senses the level
of iron in the body by sensing the amount of holo-Tf. We exam-
ined a number of hepatic cell lines for their ability to upregulate
hepcidin in response to holo-Tf and found that WIF-B cells met
the criterion. WIF-B cells are a rat hepatoma/human fibroblast
hybrid with many functional and morphological similarities to
hepatocytes (Ihrke et al., 1993). Even though they are rat/human
hybrids, others have found that they express predominantly
rat genes (Braiterman et al., 2008; Konieczko et al., 1998; Nies
et al., 1998), and we could not detect human TfR1, TfR2, or
HFE by immunoblot (M.K., unpublished data). Primers to rat
hepcidin were used to determine levels of the hepcidin transcript.
When treatedwith 25 mMholo-Tf for 24 hr,WIF-B cells expressed
2.5-fold higher hepcidin mRNA, as determined by quantitative
real-time reverse transcriptase-PCR (qRT-PCR), compared to
untreatedcells or cells treatedwithapo-Tf (Figure1A). Incontrast,
HepG2 cells, a human hepatoma cell line, do not upregulate hep-
cidin in response to Tf (Gehrke et al., 2003). Thus WIF-B cells
mimic the regulation of hepcidin levels by holo-Tf that is seen in
hepatocytes in vivo.218 Cell Metabolism 9, 217–227, March 4, 2009 ª2009 Elsevier Inc.We compared themRNA levels of the key iron-related genes in
WIF-B cells, HepG2 cells, and isolated rat hepatocytes in order
to determine the reason for the differences in hepcidin response
to holo-Tf between the two cell lines. While the TfR1 and TfR2
levels inWIF-B cells were comparable to those of freshly isolated
rat hepatocytes, HFE and HJV levels were 6- to 10-fold less in
WIF-B cells. Interestingly, the mRNA level of HFE in WIF-B cells
was about 32-fold higher than in HepG2 cells. Among other
genes involved in iron homeostasis in the body, TfR2mRNA level
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Figure 1. Hepcidin Expression in WIF-B Cells Responds to Holo-Tf
(A) Holo-Tf induces hepcidin expression in WIF-B cells. WIF-B cells were left
untreated or incubated with 25 mM human apo-Tf or holo-Tf for 24 hr prior to
RNA isolation. The hepcidin mRNA level was measured by qRT-PCR and
normalized to GAPDH.
(B) Comparison of HFE, TfR1, TfR2, and HJV mRNA levels in WIF-B cells,
HepG2 cells, and rat hepatocytes. Levels of TfR1, TfR2, HFE, and HJV
mRNA, iron-related genes upstream of hepcidin, were measured by qRT-
PCR. All samples were run in triplicate in three independent experiments.
Data are shown as average ± SD. P values < 0.05, calculated by Student’s
t test, are indicated by *.
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response. The HJV mRNA level was comparable in the two cell
lines and lower than in isolated rat hepatocytes (Figure 1B).
TfR1 levels were 5-fold higher in WIF-B cells than in HepG2 cells
and isolated hepatocytes, also implicating TfR1 in signaling.
Since the levels of HFE mRNA were substantially lower in
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Figure 2. Tf-Induced Dissociation of HFE from TfR1
Results in the Association of HFE with TfR2 and Stim-
ulates Hepcidin Promoter Activity
(A) Inducible expression of wild-type or W81A mutant HFE in
HepG2/tTA HFE and HepG2/tTA W81AHFE cells. Lysates
(25 mg) of HepG2/tTA HFE or HepG2/tTA W8AHFE cells, unin-
duced (dox) or induced (+dox) to express HFE or W81AHFE,
were detected with anti-FLAG antibody.
(B) HFE is required for Tf to induce hepcidin promoter activity
independently of interaction with TfR1. Cells were cotrans-
fected with pLuc-link-HAMP and pCMV-b-gal, treated without
(controls, indicated by the letter C) or with holo-Tf, and
analyzed as described in Experimental Procedures. Results
are expressed as average ± SD of three independent experi-
ments performed in triplicate.
(C) Hepcidin mRNA expression in HepG2/tTA (Con), HepG2/
tTA HFE (HFE), and HepG2/tTA W81AHFE (W81AHFE) cells
treated without (indicated by the letter C) or with holo-Tf as
described in Experimental Procedures. The expression of
hepcidin was measured by qRT-PCR and normalized to
GAPDH. The fold of increase in hepcidin mRNA in the dox-
induced group was obtained by normalization to uninduced
controls. All samples were run in triplicate in three indepen-
dent experiments. Data are shown as average ± SD.
(D) Tf releases HFE from TfR1 to bind to TfR2 in HepG2 cells.
Cell lysates (200 mg) from HepG2/tTA HFE treated with or
without 25 mM holo-Tf were immunoprecipitated with rabbit
anti-FLAG antibodies, and Protein A-Sepharose 4B. Proteins
were detected on immunoblots using mouse anti-TfR2,
-TfR1, -FLAG, and -actin and goat anti-Tf. The input lanes
correspond to one-fifth of thematerial used for immunoprecip-
itation. These results were repeated once with similar results.
P values < 0.001 are indicated by *** and < 0.01 by **. P values
were calculated by Student’s t test.
HepG2 cells than in WIF-B and hepatocytes, we
created a cell line, HepG2/tTA HFE, which was
stably transfected with HFE under the control of
the tetracycline-activated promoter.
HFEContributes to Tf-Sensitive Induction of
the Hepcidin Promoter Activity Independent
of TfR1
HepG2/tTA HFE cells were induced to express HFE
with doxycycline (dox), a tetracycline analog, to
test the possible role of HFE in the regulation of
hepcidin expression (Figure 2A). To observe the
effect of holo-Tf and HFE on hepcidin transcription,
HepG2/tTA HFE cells were transiently transfected
with a luciferase reporter vector, pLuc-link-HAMP,
containing human hepcidin promoter 2 kb in
length. Hepcidin promoter activity was measured
using luciferase. Holo-Tf treatment of cells had no
effect on the hepcidin promoter activity in HepG2
cells as measured by luciferase in the absence of
HFE expression (Figure 2B). The lack of response
is consistent with a previous study in HepG2 cells (Gehrke
et al., 2003), which we confirmed. HFE expression alone did not
increase hepcidin expression (Figure 2B). However, after the
induction of HFE expression with dox, holo-Tf treatment of cells
increased hepcidin promoter activity by2.7-fold. Similar results
were obtained when hepcidin mRNA levels were measured byCell Metabolism 9, 217–227, March 4, 2009 ª2009 Elsevier Inc. 219
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in mRNA levels were the result of transcriptional activation.
The finding that HepG2/tTA HFE cells increased hepcidin tran-
scription in response to holo-Tf only in the presence of HFEmade
this an ideal cell line to examine the binding partners of HFE
necessary for the holo-Tf-induced hepcidin response. We stably
transfected HepG2/tTA cells with W81AHFE to examine the role
of the TfR1/HFE complex in the regulation of hepcidin expres-
sion. W81AHFE has 5000-fold lower affinity for TfR1 (Lebron
and Bjorkman, 1999) and does not detectably coimmunoprecipi-
tate with TfR1 (Zhang et al., 2003). This mutant form of HFE does
bind to TfR2 (Chen et al., 2007). Thus, if the TfR1/HFE complex
was necessary for signaling to increase hepcidin levels, this cell
line would not increase hepcidin mRNA in response to Tf treat-
ment. The HepG2/tTA W81AHFE cells expressed amounts of
W81AHFE comparable to cells expressing HFE (Figure 2A) and
showed similarly increased hepcidin transcription (Figure 2B)
and increased hepcidin mRNA levels (Figure 2C) compared
to cells expressing wild-type HFE. These results suggested
that the interaction between HFE and TfR1 is not required for
Tf-dependent induction of hepcidin expression in HepG2 cells.
To further investigate the binding partners of HFE in the pres-
ence of holo-Tf in HepG2 cells, HFE was immunoprecipitated
and blots were probed for proteins that coprecipitated with
HFE. TfR1 coimmunoprecipitated with HFE in the absence of
addedholo-Tf, but not in thepresence of highphysiological levels
of holo-Tf consistentwith thecompetition betweenTf andHFE for
binding to TfR1 (Figure 2D). Note that these cells synthesize Tf,
but not enough holo-Tf to completely abrogate the HFE/TfR1
interaction. Prolonged treatment of cells with holo-Tf increased
intracellular iron loading, which decreased TfR1, presumably
through the destabilization of TfR1 mRNA by the IRE/IRP
pathway (reviewed inDeDomenico et al., 2008). TfR2coimmuno-
precipitated with HFE in presence of high physiological levels of
holo-Tf (25 mM). Holo-Tf treatment of cells resulted in increased
TfR2 levels (Figure 2D), consistent with previous reports that
holo-Tf stabilizes TfR2 at the protein level (Johnson and Enns,
2004; Robb andWessling-Resnick, 2004). The lack of detectable
TfR2 that coprecipitated with HFE in the absence of added holo-
Tf could reflect the lower endogenous levels of TfR2 in this cell line
than seen in cell lines transfected with TfR2 (Chen et al., 2007;
Johnson and Enns, 2004). The coprecipitation of Tf and TfR2
with HFE in the presence of higher holo-Tf concentrations indi-
cated the possibility that they form a signaling complex to
increase hepcidin expression.
TfR2 Is Necessary for the HFE-Mediated Tf Induction
of Hepcidin Expression in HepG2 Cells
We investigated the role of TfR2 in the Tf-sensitive induction of
hepcidin. HepG2/tTA HFE cells were cotransfected with TfR2
siRNA to decrease TfR2 levels and with pLuc-link-HAMP to
measure hepcidin promoter activity. Immunoblot analysis of
TfR2 showed that TfR2 was significantly reduced after transfec-
tion of cells with TfR2 siRNA (Figure 3A). The sensitivity of hepci-
din transcription to the addition of holo-Tf, as measured by the
luciferase reporter activity, was abolished by TfR2 siRNA but
not by control siRNA (Figure 3B). These results, along with our
other results, imply that both TfR2 and HFE are necessary for
Tf-induced expression of hepcidin.220 Cell Metabolism 9, 217–227, March 4, 2009 ª2009 Elsevier Inc.HFE and TfR2 Are Both Necessary for the Tf-Mediated
Induction of Hepcidin Expression in Mouse Primary
Hepatocytes
In vitro cultures of primary hepatocytes from wild-type, Hfe/,
and Tfr2245X/245X mice were used to measure the hepcidin
response of hepatocytes to holo-Tf treatment. The TfR2 (245X)
mutation causes iron overload in mice, and the orthologous
mutation, TfR2 (250X), causes HH in humans. Hfe/ mice were
on the 129/SvEvTac (129/S) background, and Tfr2245X/245X
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Figure 3. Knockdown of TfR2 Blocks Tf-Mediated Induction of
Hepcidin Expression in HepG2/tTA HFE Cells
(A) Knockdown of endogenous TfR2 in HepG2/tTA HFE cells using specific
siRNA to TfR2. Cells were transfected with control siRNA or TfR2 siRNA and
cotransfected with pLuc-link-HAMP and pCMV-b-gal, as described in Exper-
imental Procedures. To observe the efficiency of knockdown of TfR2, cell
lysates (50 mg) from TfR2 siRNA- or control siRNA-transfected HepG2/tTA
HFE cells were analyzed by immunoblot for TfR2, HFE, and actin expression.
These results were representative of one out of three experiments. Human
TfR2 siRNA significantly decreased endogenous TfR2 protein level in both
HepG2/tTA control cells and HepG2/tTA HFE cells.
(B)Hepcidinpromoter activity assay inHepG2/tTAHFEcells after knockdownof
TfR2 and treatmentwithout (indicated by the letter C) or with holo-Tf. Luciferase
and b-galactosidase activity from cell lysates was measured as described in
Experimental Procedures. Relative luciferase activity was obtained by normali-
zation to b-galactosidase activity, and the fold increase in luciferase activity
of each group was obtained by normalization to the control group without
holo-Tf. Results are expressed as average ± SD of three independent experi-
ments performed in triplicate. P values < 0.001, calculated by Student’s t test,
are indicated by ***.
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indicated that TfR2 (245X) binds HFE but not Tf in vitro (Chen
et al., 2007; Goswami and Andrews, 2006). In the primary hepa-
tocytes isolated from 129/S mice and FVB mice, we found that
hepcidin mRNA levels increased by about 3.4- and 9.9-fold
(Figure 4), respectively, in response to treatment with 25 mM
holo-Tf. These differences between the ability to stimulate hepci-
din expression in hepatocytes from the different strains of mice
could be either strain dependent or due to the expression of the
truncated TfR2. However, no significant changes of hepcidin
mRNA levels were detected in the primary hepatocytes isolated
from Hfe/ or Tfr2245X/245X mice compared with their corre-
sponding controls (Figure 4). These results strongly support the
idea that both HFE and TfR2 are required for Tf-induced hepcidin
expression and agree with the finding that HFE is necessary for
Tf-induced hepcidin expression in HepG2 cells. Consistent with
the reports that hepcidin levels are lower in Hfe/ and in Tfr2
mutant mice (Ahmad et al., 2002; Bridle et al., 2003; Muck-
enthaler et al., 2003; Nicolas et al., 2003; Wallace et al., 2007),
the hepcidin mRNA levels in the isolated primary hepatocytes
from Hfe/ and Tfr2245X/245X mice were 16.5- and 4-fold lower
than those in their corresponding wild-type counterparts
(Figure 4). Thus, both TfR2 and HFE are necessary for the induc-
tion of hepcidin by holo-Tf.
The a3 Domain of HFE Is Insufficient for the Induction
of Hepcidin Expression in HepG2 Cells in Response
to Holo-Tf
Tomap the domains of HFE responsible for the Tf-induced upre-
gulation of hepcidin, we took advantage of the findings that HFE
binds to TfR2 through itsa3domain (Chen et al., 2007), whereas it
binds to TfR1 via its a1a2 domains (Bennett et al., 2000), and that
the structures of the HFE and the MHC1 molecules are similar
(review in Wilson and Bjorkman, 1998). Two HFE-HLA-B7
chimeras were generated: a3(), in which the HFE a3 domain
was replaced with the HLA-B7 a3 domain, and a3(+), in which
the a3 domain of HFE was substituted for the a3 domain of
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129/S 129/SFVB FVB Figure 4. TfR2 and HFE Are Required for Tf-
Mediated Induction of Hepcidin Expression
in Mouse Primary Hepatocytes
Mouse primary hepatocytes were treated without
(indicated by the letter C) or with holo-Tf, and qRT-
PCR was performed on isolated RNA as described
in Experimental Procedures. Average relative level
of hepcidin was normalized to GAPDH. Results are
expressed as average ± SD of two or four inde-
pendent experiments performed in triplicate.
P values < 0.05, < 0.01, and < 0.001, calculated
by Student’s t test, are indicated by *, **, and ***,
respectively.
HLA-B7 (Figure 5A). These two
constructs, along with HLA-B7, were
transfected individually into HepG2/tTA
cells under the control of the tetracy-
cline-inducible system (Figure 5B). The
abilities of HFE chimeras to coprecipitate
TfR2 were detected by immunoblots
(Figure 5C). The a3() chimera did not
show detectable interaction with TfR2 (Figure 5C) but was able
to interact with TfR1, indicating that lack of interaction with
TfR2 was not due to misfolding of the chimera (Figure S1). TfR2
coprecipitated with both HFE and the chimera containing the
HFE a3 domain (a3[+]) but not with the negative control HLA-B7
(Figure 5C). These results confirmed our previous observation
that the a3 domain of HFE is critical for HFE binding to TfR2
(Chen et al., 2007). Surprisingly, a3(+) coprecipitated with TfR2,
but it did not mediate the Tf-sensitive induction of the hepcidin
promoter activity in the luciferase activity assay (Figure 5D).
These results imply that a3 domain of HFE is required for binding
to TfR2, but it is insufficient for regulation of hepcidinmRNAbyTf.
A Chimera Containing Both the HFE a3 Domain and
Cytoplasmic Domains Is Sufficient to Mediate Tf
Induction of Hepcidin Expression in HepG2 Cells
Since the chimera containing only the a3 domain of HFE was not
sufficient tomediate the inductionof hepcidin byTf,wegenerated
plasmidsencodingchimeraswhere thedomainsofHFEandHLA-
B7 were exchanged (Figure 6A) and stably transfected them into
HepG2/tTA cell lines (Figure 6B). Only the chimeras containing
both the a3 and cytoplasmic domains of HFE (a3tmcd and
a3cd) were able to induce luciferase activity (Figure 6C). The
a1a2 chimera interacted with TfR1, indicating that the lack of
stimulation of luciferase activity is not due to misfolding of the
chimera (Figure S1). Thus, the a3 and cd domains of HFE on the
HLA-B7 backbone are necessary and sufficient to stimulate
hepcidin transcription in response to treating cells with holo-Tf.
DISCUSSION
The liver plays a key role in the sensing of iron levels in the body
and in the regulation of iron homeostasis. Hepatocytes within
the liver express proteins critical to these processes, including
HFE, TfR2, HJV, and Tf, aswell as the peptide hormone hepcidin.
Hepcidin, which negatively regulates iron efflux fromcells into the
blood, is controlled at the transcriptional level. Thus, when theCell Metabolism 9, 217–227, March 4, 2009 ª2009 Elsevier Inc. 221
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Figure 5. The a3 Domain Is Required but Insufficient for HFE-Mediated Tf Induction of Hepcidin Expression in HepG2 Cells
(A) Schematic representation of the HFE mutant and chimeras, including HFE, W81AHFE, a3(), a3(+), and HLA-B7. HFE is shown in gray; HLA-B7 is shown in
white. Numbers under diagrams for each full-length protein designate the first amino acid in the signal sequence (SS), a1a2 domain (a1a2), a3 domain (a3), trans-
membrane domain (tm), and cytoplasmic domain (cd). FLAG epitope tag (-f) was added to the C terminus of each protein. HFE-HLA-B7 chimeras were222 Cell Metabolism 9, 217–227, March 4, 2009 ª2009 Elsevier Inc.
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inhibit further iron uptake and results in iron sequestration in cells.
In this study, we examined the roles of these key proteins in
controlling hepcidin expression in cell lines that were engineered
to mimic the increase in hepcidin in normal hepatocytes in
constructed by replacing the appropriate segments between the parent proteins. The first coding methionine in all proteins is labeled as number 1. We refer to
individual recombinant proteins used throughout the study by acronyms to the left of the construct illustration.
(B) Induction of HFE chimeras by dox. Lysates (25 mg) of HepG2/tTAHFE, HepG2/tTA a3(), HepG2/tTA a3(+), andHepG2/tTA HLA-B7 cells, uninduced (dox) or
induced (+dox) to express wtHFE, a3(), a3(+), or HLA-B7, were detected using mouse anti-FLAG antibody.
(C) The a3 domain of HFE is critical for interaction with TfR2 in HepG2/tTA cells. Cells lysates (200 mg) were immunoprecipitated with rabbit anti-FLAG antibody,
and the blots were probed with mouse antibodies to TfR2, FLAG, and actin. The input lanes correspond to one-fifth of the material used for immunoprecipitation.
These results were repeated once with similar results.
(D) The a3 domain of HFE is required but insufficient for HFE-mediated Tf induction of hepcidin expression in HepG2 cells. Cells were cotransfected with pLuc-
link-HAMP and pCMV-b-gal plasmids, treated without (indicated by the letter C) or with 25 mM holo-Tf (holo-Tf), and analyzed as described in Experimental
Procedures. Results are expressed as average ± SD of three independent experiments performed in triplicate. P values < 0.001, calculated by Student’s
t test, are indicated by ***.
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Figure 6. The a3 and Cytoplasmic Domains of HFE
Mediate the Tf Induction of Hepcidin Expression in
HepG2 Cells
(A) Schematic representation of the HFE chimeras, including
a1a2, a3tmcd, a3cd, and cd constructs. HFE is shown in
gray; HLA-B7 is shown in white. HFE chimeras were con-
structed by replacing the appropriate segments between the
parent proteins. Individual recombinant proteins used
throughout the study are referred to by the acronyms to the
left of the construct cartoon.
(B) Generation of HFE-HLA-B7 chimeras. HFE chimeras,
including stable cells lines HepG2/tTA a1a2, HepG2/tTA
a3tmcd, HepG2/tTA a3cd, andHepG2/tTA cd,were generated
as described in Experimental Procedures. Lysates (25 mg) of
cells, uninduced (dox) or induced (+dox), were used to screen
the positive clones by immunoblot using anti-FLAG antibody.
(C) The a3 and cytoplasmic domains of HFE are required for
HFE-mediated Tf induction of hepcidin expression in HepG2
cells. All HepG2/tTA control and HFE chimera cells were
cotransfected with pLuc-link-HAMP and pCMV-b-gal, treated,
and analyzed as described in Experimental Procedures.
Results are expressed as average ± SD of three independent
experiments performed in triplicate. P values < 0.001 are indi-
cated by *** and < 0.01 by **. P values were calculated by
Student’s t test.
response to treatment with a physiological concen-
tration of holo-Tf. We found that the Tf/TfR2/
HFE complex was necessary to increase hepcidin
expression.
The Role of Tf in the Regulation of Hepcidin
The concentration of holo-Tf in blood has been
proposed to be a regulator of hepcidin expression
(Johnson and Enns, 2004; Robb and Wessling-
Resnick, 2004). High holo-Tf levels correlate with
increased hepcidin mRNA in the liver (Kawabata
et al., 2005). The finding that hepcidin levels
increase in freshly isolated mouse hepatocytes
(Lin et al., 2007) in response to holo-Tf demon-
strates that hepatocytes can respond directly.
Holo-Tf serves two functions in the regulation of
hepcidin. First, it alters the interactions between
HFE and TfR1. A recent study examined the role
of TfR1 in the control of hepcidin mRNA levels by generating
mice that express a mutant TfR1 that does not bind detectably
to HFE (Schmidt et al., 2008). A higher level of hepcidin mRNA
was detected in the TfR1mutant mice than in the strain-matched
control mice. The authors propose that increased hepcidinCell Metabolism 9, 217–227, March 4, 2009 ª2009 Elsevier Inc. 223
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partner. They speculate that the binding partner was TfR2 based
on previous evidence showing that HFE is capable of binding to
TfR2 (Chen et al., 2007; Goswami and Andrews, 2006). They also
suggest that the TfR2/HFE complex is responsible for hepcidin
regulation, and that TfR1 sequesters HFE from binding to TfR2
under low levels of holo-Tf. In our study, we showed that disrup-
tion of the HFE/TfR1 complex alone did not regulate hepcidin
expression using transfected hepatoma cell lines. Upregulation
of hepcidin mRNA was achieved only in the presence of holo-
Tf and TfR2. In addition, we directly demonstrated that Tf/
TfR2/HFE complex is involved in the upregulation of hepcidin.
Thus, the Tf/TfR2/HFE complex is critical for increased hepcidin
expression. How the complex signals to accomplish this remains
to be determined.
The second way that Tf can modulate the HFE/TfR2 interac-
tions is through the downregulation of TfR1 and the upregulation
of TfR2. Thus, under high-iron conditions, increased saturation
of Tf with iron results in an increased amount of Tf/TfR2/HFE
complex, and together with the results from mice with mutated
TfR1, these findings indicate that Tf binding to TfR1 releases
HFE to form a complex with Tf and TfR2. This complex is respon-
sible for increased hepcidin expression. This model predicts that
HFE is limiting for complex formation. Future experiments will
focus on testing this prediction.
The Necessity of HFE in the Tf-Mediated Sensitivity
of Hepcidin
The changes in hepcidin mRNA in WIF-B and HepG2/tTAHFE
cells are within physiological responses. They are similar to the
3- to 4-fold increase in hepcidin levels in mice fed high-iron diets,
although there is variability in response between strains (Bondi
et al., 2005) and our findings in primary hepatocytes. The require-
ment of HFE for increased hepcidin expression in response to
Tf treatment is consistent with the lack of hepcidin response in
Hfe/ mice on a high-iron diet (Ahmad et al., 2002). Our results
suggest that HFE is required for the Tf-induced hepcidin expres-
sion in hepatocytes and are in keeping with the recent finding
that hepatocyte-specific expression of HFE increases hepcidin
levels in mice (Schmidt et al., 2008; Vujic Spasic et al., 2008).
Since HFE affects other aspects of iron homeostasis indepen-
dent of hepcidin (Gao et al., 2008), lack of HFE could also have
other effects on iron metabolism in Hfe/ mice.
The Role of TfR2 in the Upregulation of Hepcidin
in Response to Tf
In addition to the role of HFE and Tf in the control of hepcidin
mRNA, we also showed that TfR2, which binds to HFE in vitro,
is required for Tf-dependent stimulation of hepcidin expression.
Holo-Tf treatment of cells also increases TfR2 levels by stabi-
lizing TfR2, thus also promoting the formation of the TfR2/HFE
complex. Knockdown of TfR2 or lack of functional TfR2 results
in loss of hepcidin sensitivity to Tf treatment. These results
help to explain why Tfr2/ mice have 3- to 4-fold lower basal
hepcidin levels despite hepatic iron overload. They also explain
the lack of hepcidin response to iron in the Tfr2/mice (Wallace
et al., 2007) and why Tf failed to increase hepcidin expression in
primary hepatocytes isolated from Tfr2245X/245X mice.224 Cell Metabolism 9, 217–227, March 4, 2009 ª2009 Elsevier Inc.Mapping the Domains of HFE that Are Responsible
for the Tf-Induced Upregulation of Hepcidin
To further investigate the involvement of TfR2/HFE complex in
the Tf induction of hepcidin expression, HFE/HLA-B7 chimeras
were used. Intriguingly, the HFE-HLA-B7 chimera containing
only the HFE a3 domain bound to TfR2 but did not alter hepcidin
expression in presence of holo-Tf. These results suggest that
a3 domain of HFE is necessary but not sufficient for Tf-induced
stimulation of hepcidin expression. Further domain mapping
using HFE/HLA-B7 chimeras showed that both the a3 and cyto-
plasmic domains of HFE were required for HFE regulating hepci-
din. The role of the cytoplasmic domain with respect to hepcidin
regulation still remains to be clarified.
Hepcidin mRNA is transcriptionally regulated through at least
three pathways. Interleukin 6 stimulates hepcidin expression
through the STAT3 signaling pathway. Bone morphogenic
proteins, BMPs, increase hepcidin expression through the HJV/
BMP receptor/Smad 4 pathway. Tf stimulates hepcidin expres-
sion throughaTfR2-/HFE-mediatedpathway.Theextent towhich
these pathways are interconnected is unknown.Mutations inHJV
can cause juvenile hemochromatosis, a severe iron overload
disease characterized by low hepcidin levels. Similarly, Hjv/
mice have extremely low hepcidin levels, but the levels can be
further decreased by phlebotomy (Krijt et al., 2007), implying
that iron signaling can be independent of HJV, and that HJV
participates in establishing a set point for BMP signaling and
iron homeostasis. Whether the Tf control of hepcidin signaling is
through any of these signaling pathways is still unresolved.
Taken together, our studies suggest that the Tf/TfR2/HFE
complex is involved in the sensing of Tf saturation, which leads
to the regulation of hepcidin expression. Based on these results,
mutations in either HFE or TfR2 should result in a similar iron
overload disease with respect to the regulation of hepcidin.
EXPERIMENTAL PROCEDURES
Hepcidin Promoter Construct
A fragment of the human hepcidin promoter consisting of the first 2043 nucle-
otides upstreamof the translational start site was subcloned into the promoter-
less luciferase reporter vector pLuc-link as described previously (de Wet et al.,
1987; Verga Falzacappa et al., 2008) and detailed in the Supplemental Data.
HFE Chimera Constructs
The plasmids containing HFE-a1a2/HLA-B7-a3 /HFE-tmcd (a3[]), HLA-
B7-a1a2/HFE-a3/HLA-B7-tm/HFE-cd (a3cd), and HLA-B7-a1a2a3tm/HFE-
cd (cd) were constructed by overlapping PCR using the primers and templates
listed in Table S1. The wild-type HFE, W81AHFE, HFE-a1a2/HLA-B7-a3tmcd
(a1a2), HLA-B7-a1a2/HFE-a3tmcd (a3tmcd), HLA-B7-a1a2/HFE-a3/HLA-
B7-tmcd (a3[+]), and wild-type HLA-B7 constructs were generated as previ-
ously described (Chen et al., 2007; Cherry et al., 2008). All constructs contain
a C-terminal FLAG tag sequence for immunodetection. In all cases, the gel-
purified PCR products were first inserted into the pGEM-T (Promega;
Madison, WI), followed by subcloning into the pcDNA4 vector that had been
modified by adding tetracycline-inducible promoter (Feng and Longmore,
2005). All of the sequences and orientations were verified.
Antibodies
Mouse anti-hTfR2 (9F8-1C11) monoclonal antibodies were described previ-
ously (Vogt et al., 2003). M2 anti-FLAG, H68.4 anti-TfR1, and anti-actin were
purchased from Sigma-Aldrich (St. Louis, MO); Zymed Laboratories, Inc.
(San Francisco, CA); and Sigma-Aldrich, respectively. Secondary antibodies
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were purchased from Chemicon (Temecula, CA).
Cell Culture and Transfection
WIF-B cells, obtained from Doctor Ann Hubbard (Johns Hopkins University),
were grown in F-12 Coon’s Modification with amphotericin, glutamax, peni-
cillin/streptomycin supplemented with HAT, and 5% FCS and cultured in
a humidified 7%CO2 incubator at 37
C (Ihrke et al., 1993). Tetracycline-induc-
ibleHepG2cells (HepG2/tTA)wereobtained fromDoctorGregoryD. Longmore
(Washington University in St. Louis) and grown in DMEM containing 10% FBS,
2 mM L-glutamate, and 5 mg/ml blasticidin (Feng and Longmore, 2005). To
generate HepG2/tTA cells stably expressingHFE chimeras, individual pcDNA4
constructs encoding the specified chimeric HFEs or HLA-B7 were introduced
using Nucleofector Kit V (Amaxa Biosystems; Gaithersburg, MD). Stable cell
clones were obtained under the selection with 1 mg/ml G418. Positive clones
in the presence of doxycyline (dox) were screened using anti-FLAG antibody.
We generated the following stable cell lines: HepG2/tTA HFE, HepG2/tTA
W81AHFE, HepG2/tTA a3(), HepG2/tTA a3(+), HepG2/tTA a1a2, HepG2/
tTA a3tmcd, HepG2/tTA a3cd, HepG2/tTA cd, and HepG2/tTA HLA-B7 cells.
Isolation of Mouse Primary Hepatocyte Cells
Mouse primary hepatocytes were isolated as described in Supplemental Data.
Tf Treatment of Cells
WIF-B cells were seeded in 6-well plates and treated with 25 mM holo-Tf or
apo-Tf (Athens Research and Technology; Athens, GA) for 24 hr prior to har-
vesting cells. HepG2/tTA cell lines were seeded in 6-well plates, and after
24 hr, themediumwas replaced with FBS-free medium in the absence or pres-
ence of 25 mMhuman holo-Tf for 24 hr prior to harvest. To induce expression of
HFE, HLA-B7, or the chimeras in HepG2/tTA cell lines, 200 ng/ml dox was
added to the medium 24 hr before Tf treatment.
Immunoblot
Preparation of cell lysates is described in Supplemental Data. Immunoblot
analysis was carried out using M2 anti-FLAG (1:10,000), mouse monoclonal
anti-TfR2 (1:10,000, 9F8-1C11), H68.4 anti-TfR1 (1:5000), and mouse anti-
actin (1:10,000) followed by anti-mouse secondary antibodies conjugated to
HRP (1:10,000). Bands were detected by enhanced chemiluminescence
(SuperSignal West Pico; Pierce; Rockford, IL).
Immunoprecipitation
Cell lysate (100 mg protein) was first precleared with Protein A-Sepharose
4B beads (Zymed; San Francisco, CA) for 1 hr at 4C. The precleared lysates
were rotated for 2hrat4Cwith rabbit anti-FLAGantibodyandProteinA-Sephar-
ose 4B. Immunoprecipitated complexeswerewashed by centrifugation through
1% NET-Triton buffer containing 15% sucrose and eluted with 2 3 Laemmli
buffer (Laemmli, 1970). Immunodetection was performed as described above.
Knockdown of TfR2
Lipofectamine 2000 (Invitrogen; Carlsbad, CA) was used to cotransfect siRNA
specific for human TfR2 (Dharmacon; Chicago, IL) or negative control siRNA
and pLuc-link-HAMP as well as pCMV-b-gal plasmid following the manufac-
turer’s instructions. Briefly, HepG2/tTA HFE cells in 28 cm2 dishes were trans-
fected with a mix of 10 ml of 20 mM TfR2 siRNA, 2 mg pLuc-link-HAMP, and
0.1 mg pCMV-b-gal plasmids using 10 ml Lipofectamine 2000 (Gao et al.,
2008; Zhang et al., 2007). Control cells were incubated with the same amounts
of control siRNA, pLuc-link-HAMP, and pCMV-b-gal plasmids using 10 ml Lip-
ofectamine 2000. The concentration of siRNA (100 nM) had been optimized to
maximally decrease TfR2 levels. One day after the transfection, cells were split
into 12-well plates, and on the following day, cells were switched to the FBS-
free medium and incubated with or without 25 mM holo-Tf for additional 24 hr
prior to harvesting.
Quantitative Real-Time Reverse Transcriptase-PCR
Total RNA from HepG2 cells, WIF-B cells, rat hepatocytes, or mouse primary
hepatocytes was isolated from cells using the RNeasy RNA isolation kit
(QIAGEN; Valencia, CA) and treated with DNase (Roche Applied Science) to
remove any contaminating genomic DNA. Rat hepatocytes (n = 3) were fromCnormal male Wistar rats. Hepatocytes were isolated by the Cell Culture Core
of the USCResearch Center for Liver Diseases as previously described (Zhang
et al., 2004). Oligo (dT) primers and Superscript II reverse transcriptase were
used to synthesize cDNA according to manufacturer’s instructions. Hepcidin,
TfR1, TfR2, HFE, HJV, and GAPDH mRNA were measured using the rat or
human primers listed in Table S2 and as previously described (Gao et al.,
2008; Zhang et al., 2007). Results were expressed as the level relative to the
corresponding GAPDH. All primers were verified for linearity of amplification.
Transient Transfections and Luciferase Assays
Control or transfected HepG2/tTA cells were seeded in 78 cm2 dishes and
cotransfected with pLuc-link-HAMP (5 mg) and pCMV-b-gal plasmids (0.25 mg)
usingLipofectamine (50ml).On the followingday, the cellswere split into12wells
of a 12-well plate. They were treated with FBS-free medium ± 25 mM holo-Tf
for 24 hr. Cells were lysed in NET-Triton buffer, followed by centrifugation
at 16,000 g for 5 min at 4C to remove cell debris. The luciferase activities of
supernatants were measured and normalized to b-galactosidase activity as
previously described (Kim et al., 1994; Martin et al., 1996) and normalized with
the control (-Tf).
Statistical Analysis
Standard deviation (SD) and the paired and two-tailed Student’s t tests were
used to evaluate the statistical significance of qRT-PCR and luciferase assay
data.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, two
tables, and one figure and can be found online at http://www.cell.com/
cellmetabolism/supplemental/S1550-4131(09)00035-7.
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